Company: TVRD
Filing Date: 2025-11-13
Form Type: 10-Q
Source: 0001104659-25-111289
Chunk: 2

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-11-13
Form: 10-Q
Item: Part I, Item 1
Chunk 2
---
 30, 2025 and December 31, 2024, respectively​  —​  85,503​​​​​​​​​Stockholders' Equity (Deficit):​   ​   ​Common stock, $0.001 par value; 150,000,000 shares and 58,251,629 shares authorized as of September 30, 2025 and December 31, 2024, respectively; 9,379,332, and 2,574,767 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively​  9​  2​Additional paid-in capital​  131,025​  1,103​Accumulated other comprehensive income​​ 7​​ —​Accumulated deficit​​ (103,175)​  (92,236)​Total stockholders' equity (deficit)​  27,866​  (91,131)​Total liabilities, redeemable convertible preferred stock, and stockholders' equity (deficit)​$ 39,021​$ 35,199​

​

The accompanying notes are an integral part of these condensed consolidated financial statements.

​